Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy A STROBE-compliant observational study


Creative Commons License

Esatoglu S. N. , Hatemi G. , Ugurlu S., Gokturk A., Tascilar K., Ozdogan H.

MEDICINE, cilt.96, 2017 (SCI İndekslerine Giren Dergi) identifier identifier identifier

Özet

There are no treatment modalities, which were proven to prevent the deposition of amyloid, proteinuria, and loss of renal function due to amyloidosis. Anti-tumor necrosis factor agents (anti-TNFs) were shown to decrease the production of serum amyloid A protein. We aimed to evaluate the long-term efficacy and safety of anti-TNFs in secondary (AA) amyloidosis patients treated in a single center.